About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, May 12th, 2017

The QualityStocks
Daily Stock List


Patriot Gold Corp. (PGOL)

Marketbeat reported earlier on Patriot Gold Corp. (PGOL), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Patriot Gold Corp. is a precious metals exploration and production company. Its mission is to discover and develop significant gold and silver assets in Arizona and Nevada. At present, the Company holds a portfolio of four projects. These are the Moss project in Arizona and three in Nevada (Bruner, Vernal, and Windy Peak). Patriot Gold holds a 3 percent royalty in the Moss Mine in Arizona, a 30 percent interest in the Bruner gold project in Nevada, and a 100 percent interest in the Vernal and Windy Peak projects in Nevada. OTCQB-listed, Patriot Gold is headquartered in Las Vegas, Nevada.

The Moss Mine Project is within the historic Oatman District, 10 miles east of Bullhead City, Arizona and roughly 70 miles southeast of Las Vegas. The Moss Mine is owned by Northern Vertex Mining Corp. On April 20, 2017, Northern Vertex confirmed receipt of the final permitting document required before the start of commercial production (Aquifer Protection Permit signed by Water Quality Division Arizona Department of Environmental Quality). All operating permits have now been received. The Moss Mine is scheduled to begin commercial gold-silver production in Q4 2017.

Patriot Gold’s Vernal gold project is in its early stage. The property is about 140 miles east-southeast of Reno, Nevada on the west side of the Shoshone Mountains. The property consists of 12 unpatented mining claims (240 acres).

The Bruner gold project property is roughly 130 miles east-southeast of Reno, Nevada at the northern end of the Paradise Range and 45 miles northwest of the Round Mountain Mine. Patriot Gold has increased its holdings from 22 claims to 56 claims. This brings the total unpatented claims held to about 900 acres. Patriot Gold now controls all of the Bruner Mining District.

In addition, the Windy Peak Gold Project consists of 79 unpatented mineral claims in the Fairview mining district in southwest Nevada. Windy Peak is easily accessed, and is approximately 45 miles southeast of Fallon and 6 miles from Middlegate.

Canamex Resources Corp. (CNMXF) and Patriot Gold have now closed the transaction wherein Canamex Resources purchased Patriot Gold's 30-per-cent working interest in the Bruner gold/silver mine for US$1.0 million cash. Patriot retains a 3 percent net smelter return (NSR) royalty on the Bruner properties. This includes any claims acquired within a two-mile area of interest around the existing claims. Furthermore, Canamex has the option to buy-down half of the NSR royalty retained by Patriot Gold for US$5 million any time during a five-year period following closing of the purchase and sale agreement.

Yesterday, Patriot Gold announced that its common shares were approved for trading on the Canadian Securities Exchange.

Patriot Gold Corp. (PGOL), closed Friday's trading session at $0.08842, down 1.64%, on 70,450 volume with 4 trades. The average volume for the last 60 days is 66,931 and the stock's 52-week low/high is $0.0693/$0.23.

Enumeral Biomedical Holdings, Inc. (ENUM)

We are reporting on Enumeral Biomedical Holdings, Inc. (ENUM) today, here at the QualityStocks Daily Newsletter.

Enumeral Biomedical Holdings, Inc. is focusing on the discovery and advancement of next generation therapeutics in cancer, auto-immune, and other diseases. The Company is discovering and developing novel antibody immunotherapies, which assist the immune system in attacking diseased cells. Enumeral is building a pipeline of immunomodulators for the treatment of cancer and inflammatory diseases and leveraging the extensiveness of its technology through strategic collaborations. Enumeral Biomedical Holdings is based in Cambridge, Massachusetts. The Company’s shares trade on the OTCQB.

Enumeral’s distinctive platform enables it to identify and characterize promising new drugs relevant to cancer, infectious, and inflammatory diseases. The Company is enabling and speeding up the discovery and development of novel antibody immunotherapies, or immunomodulators that are validated with its human-driven immune profiling platform. Its immunoprofiling platform harnesses The Power of Human™.

Enumeral employs a proprietary microwell array technology to identify cell type and measure functioning of individual cells from tissue samples, and to retrieve individual live cells of interest, for cell culture or gene cloning. This technology provides important insights for target validation, drug candidate selection, and rational drug development. Additionally, the Company has built a pipeline of immune checkpoint modulators for targets. These include PD-1, TIM-3, CD39, and others.

The core technology underlying the Company’s platform was developed at, and licensed from, the Massachusetts Institute of Technology (MIT), Harvard University, and Whitehead Institute for Biomedical Research and Massachusetts General Hospital.

Enumeral Biomedical is continuing to pursue its pipeline of antibody candidates. This includes its PD-1 antibody program. It selected one of its lead anti-PD-1 antibody candidates, called ENUM 244C8, for further development.

Recently, Enumeral Biomedical Holdings announced that it and the International Consortium on Anti-Virals (ICAV) entered into a Memorandum of Understanding (MOU) to pursue an infectious disease collaboration using Enumeral's proprietary platform. The aim of the collaboration is to isolate and characterize high affinity, broadly neutralizing human antibodies against select human pathogens from patients previously infected or vaccinated for therapeutic intervention, prophylaxis, and/or diagnostic utility.

With this collaboration, ICAV would provide patient samples, reagents for target screening from their global collaborator network, and critical functional screening. Enumeral Biomedical Holdings will use its proprietary platform to identify high affinity antibodies and provide sufficient quantities for testing and candidate selection.

Enumeral Biomedical Holdings, Inc. (ENUM), closed Friday's trading session at $0.121, up 42.35%, on 78,399 volume with 16 trades. The average volume for the last 60 days is 55,200 and the stock's 52-week low/high is $0.072/$0.24.

U-Vend, Inc. (UVND)

Stock Commander, ProTrader, StockRockandRoll, SmallCapVoice, PennyStockLocks, MicroCapDaily, OTCMagic, Winston Small Cap, OTPicks, Stocks To Watch, Penny Stock Beats, MyBestStockAlerts, PennyStockInformer, PennyStockLaboratory, and PennyStocks24 reported earlier on U-Vend, Inc. (UVND), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Established in 2009, U-Vend, Inc. is a consumer products and automated retailing company. It creates, markets, and sells unique ice cream and related food products that undergo distribution to retail markets using different next-generation self-serve electronic kiosks throughout North America. U-Vend is headquartered in Santa Monica, California. The Company also has offices in Orange, California; and Las Vegas, Nevada. U-Vend USA LLC established in April 2010.

U-Vend owns and operates kiosks. The Company develops, distributes, and markets next-generation self-serve electronic kiosks and merchandisers with a digital advertising component. U-Vend has partnered with many national consumer product companies to deliver new and innovative customer retail experiences in automated frictionless settings.

The Company has four market segments: Environmental, Retail, Service, and Mall/Airport Islands. U-Vend’s focus is Environmental and Retail. It has designed a Mall and Airport Multipurpose Island. U-Vend took many of its Self-Serve kiosks and bundled them into an "island", all in one central location. This has created a destination concept within a mall and/or airport setting. The island is always associated with a co-branding anchor as part of the complete concept.

In some cases, U-Vend kiosks are wireless, managed on line 24/7, and accept credit and debit cards. In Retail kiosks, a touch screen catalogue is provided for customers to scroll through and review all products being provided in the kiosk.  

U-Vend’s customer base comprises retail installations, co-branding partnerships, direct sales, and the general population wanting to own their own business. U-Vend end-users include national chains, independent owner operators, big box stores, restaurants, malls, airports, casinos, universities, and colleges, among others. U-Vend offers low-cost investment with the potential for high returns. 

Last month, U-Vend announced its financial results for the year ended December 31, 2016. Revenues for the twelve months ended December 31, 2016 grew 60.2 percent to $1,428,045 versus Revenue of $891,227 for the twelve months ended December 31, 2015. Gross Profits increased 103 percent to $714,175 versus Gross Profit of $351,228 for the year ended December 31, 2015.

Gross Margin rose to 50 percent versus Gross Margin of 39 percent for the year ended December 31, 2015.  The Company’s Net Loss for the year rose 27 percent to $2,607,461 versus a Net Loss of $2,050,574 for the year ended December 31, 2015.

U-Vend, Inc. (UVND), closed Friday's trading session at $0.03, up 84.05%, on 231 volume with 3 trades. The average volume for the last 60 days is 14,557 and the stock's 52-week low/high is $0.0151/$0.185.

Dakota Territory Resource Corp. (DTRC)

Innovative Marketing, OTC Markets Group, and UltimatePennyStock reported earlier on Dakota Territory Resource Corp. (DTRC), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Dakota Territory Resource Corp.’s focus is on the acquisition and responsible exploration and development of high caliber gold properties in the Black Hills of South Dakota. The Company maintains 100 percent ownership of three mineral properties. These include the Blind Gold, City Creek, and Homestake Paleoplacer Properties. All of them are in the heart of the Homestake District. Dakota Territory Resource has its headquarters in Reno, Nevada.

The Blind Gold Property is its flagship property. It is a target for Tertiary-aged and Iron-formation gold mineralization. The Blind Gold Property is roughly four miles northwest and on structural trend with the historic Homestake Gold Mine. The Homestake Gold Mine produced about 40 million ounces of gold through its 125-year production history. It is the largest iron-formation-hosted gold deposit worldwide.

In March 2016, Dakota Territory Resource announced that its intention is to continue its sampling program along trend of the zone of high grade gold mineralization identified by the first pass surface sampling program conducted on its 100 percent owned Blind Gold Property. The program identified a zone of high-grade gold mineralization in the Mississippian-age Pahasapa Limestone on the surface, with a peak gold assay value of 9.44 grams per tonne. The Company is preparing for drilling in the Homestake Gold District of South Dakota.

The Company’s City Creek Property is a target for Homestake iron-formation gold mineralization. City Creek consists of 21 unpatented lode mining claims positioned one-mile northeast of the Homestake Open Cut and one-mile northwest of the City of Deadwood. The Homestake Paleoplacer Property consists of 13 unpatented lode mining claims located one-mile north of the Homestake Open Cut. Dakota Territory Resource based the acquisition of its Black Hills property position on over 44 years of combined mining and exploration experience in the Homestake District.

In April of this year, the Company announced that it entered into agreements with Trucano Novelty, Inc. to acquire a combination of surface and mineral title to 284 acres situated in the Homestake District of the Northern Black Hills of South Dakota. Dakota’s property acquisition is consistent with its business development strategy of expanding its high quality mining interests within the Homestake District. The Company now holds roughly 3,341 acres in the heart of the district.

Dakota Territory Resource Corp. (DTRC), closed Friday's trading session at $0.0766, up 18.39%, on 2,120 volume with 6 trades. The average volume for the last 60 days is 13,623 and the stock's 52-week low/high is $0.023/$0.20.

Almost Never Films, Inc. (HLWD)

MarketWatch, The Street, and Bloomberg reported on Almost Never Films, Inc. (HLWD), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Almost Never Films, Inc. is an independent film company headquartered in Sherman Oaks, California. The Company’s focus is on film production and production related services in connection with production costs in the $5.0 million to $50.0 million range. Its business is to enable relationships between creative talent and companies who produce, finance, and distribute motion pictures. Almost Never Films lists on the OTC Bulletin Board.

The Company’s intention is to create, acquire, or license rights to materials upon which it believes motion pictures can be based. Mr. Danny Chan is the Chief Executive Officer (CEO) of Almost Never Films. Additionally, he is a Managing Director of Iconic Private Equity Partners, based in Hong Kong. Mr. Chan has spent more than 11 years investing and advising Greater China companies.

Mr. Derek Williams is the Chief Operating Officer (COO) of Almost Never Films. Mr. Williams has more than 13 years’ experience working on visual effects in Hollywood.

Almost Never Films has its partnership with Konwiser Brothers Media (KBM) to develop and produce the motion picture project "Field Trip". The Konwiser Brothers are industry leaders in writing, producing, directing and marketing award-winning theatrical films, documentaries, cable and network movies & series, and other entertainment media. Their award-winning credits include the HBO film "Miss Evers' Boys" and the documentary "On Hallowed Ground".

Mr. Danny Chan and Mr. Frank Gillen will serve as executive producers. Mr. Kip Konwiser and Mr. Kern Konwiser of Konwiser Brothers Media will be involved as the lead producer, writer and director. The deal was negotiated by Mr. Chan and Mr. Kip Konwiser of KBM.

In addition, Almost Never Films and Saisam Entertainment are partnering to develop and produce the motion picture project "Love Is Not Easy." Danny Chan, Frank Gillen, and Brian Hooks, President of Saisam Entertainment, will serve as lead producers of the film. In addition, Brian Hooks will also be engaged as the writer and director of the movie.

Saisam Entertainment will contribute its development and producing services and the original screenplay. Almost Never Films will make financial contributions and participate in the development and production process to make the movie a box office success.

Almost Never Films, Inc. (HLWD), closed Friday's trading session at $0.065, up 80.06%, on 530 volume with 2 trades. The average volume for the last 60 days is 115,263 and the stock's 52-week low/high is $0.01/$0.08.


The QualityStocks
Company Corner


Kootenay Zinc Corp. (CSE:ZNK) (OTCQB:KTNNF)

The QualityStocks Daily Newsletter would like to spotlight Kootenay Zinc Corp. (KTNNF). Today, Kootenay Zinc Corp. closed trading at $0.14, off by 13.58%, on 156,033 volume with 71 trades. The stock’s average daily volume over the past 60 days is 73,597, and its 52-week low/high is $0.1197/$0.59.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Kootenay Zinc Corp. (CSE: ZNK) (OTCQB: KTNNF), an NNW client focused primarily on discovering large-scale sedimentary-exhalative ("SEDEX") zinc deposits. The publication is entitled, "With Zinc Prices and Global Deficit on the Rise, Savvy Mining Companies are Poised to Profit." It provides an overview on worldwide shortage of zinc, and the various mining companies cashing in on the opportunity to shrink the gap between supply and demand while taking advantage of rising value. To view the full publication, visit: https://www.networknewswire.com/zinc-prices-global-deficit-rise-savvy-mining-companies-poised-profit/

Kootenay Zinc Corp. (KTNNF) is a mineral exploration and development company focused on discovering large-scale sedimentary-exhalative ("SEDEX") zinc deposits. Based in Vancouver, British Columbia, the company is ideally positioned near its primary target, the Sully Property, located 18 miles east of the world-class Sullivan Mine.

Of the 22 raw materials tracked by the Bloomberg Commodity Index, zinc was the best-performing base metal in 2016. Based on a widening global supply deficit, outlook for the commodity remains strong. As the most closely tied base metal to the Chinese economy, zinc demand and prices are expected to rise well into the year 2020, putting increased pressure on zinc supply.

For 2017, Goldman Sachs has predicted a 360,000 ton shortage of zinc, along with a subsequent rise in zinc prices to $2,500 per metric ton in the first half of the year. Zinc continues to make history in the metals exchange, driving significant interest in the market amid supply constraints in concentrates and refined metal drive prices.

Ready to claim its share of the market, Kootenay Zinc is focused on its Sully Property. It comprises 1,375 hectares and overlies rocks of similar age and origin as those which host the legendary Sullivan deposit. The Sullivan mine was discovered in 1892, and is known to be one of the world's largest SEDEX deposits. Over its 100-year lifetime, Sullivan produced approximately 150 million tonnes of ore, including approximately 300 million ounces of silver, 8 million tonnes of zinc and 8 million tonnes of lead.

Notably, geophysical data suggests that Kootenay Zinc's Sully project and Sullivan share many geological features:

  • Strata at Sully are in the same sedimentary basin as the Sullivan mine
  • The exact stratigraphic time horizon at which Sullivan formed is present at Sully
  • Filtered AeroMag anomalies coincident with Sullivan Time at Sully appear similar to Sullivan
  • Gravity anomaly at Sully indicates excess mass of comparable magnitude to Sullivan
  • Pb-Zn is present as traces in outcrop, drill core and in a soil geochemical anomaly

The squeeze in zinc supplies particularly affects China, which is both the world's largest zinc consumer and its largest producer, with 4.9 million tons of output in 2015. Chinese manufacturers are now being forced to import zinc for use in cars, household appliances, paints, rubber products and smartphones.

Zinc's rally shows no sign of slowing down in the near future, and companies that currently occupy stake in a zinc deposit find themselves in an enviable position over miners rushing to find new reserves. With its Sully Project, Kootenay Zinc could be on track to capture its share of the market, guided by a management team of mining directors and executives that currently lead some of the world's best mining companies and have been involved in world-class discoveries which sold for billions of dollars. The company's technical team includes industry experts that have worked on mega-mining projects, including the Sullivan and Voisey Bay projects. Disclaimer

Kootenay Zinc Corp. Company Blog

Kootenay Zinc Corp. News:

NetworkNewsWire Announces Publication on the Bullish Outlook for Zinc and the Companies Set to Profit

Kootenay Zinc Corp.: Sully Project Exploration Update

Kootenay Zinc Corp. (CSE: ZNK) (OTCQB: KTNNF) is “One to Watch”

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0358, up 5.29%, on 1,431,782 volume with 134 trades. The stock’s average daily volume over the past 60 days is 5,851,129, and its 52-week low/high is $0.0062/$0.142.

Singlepoint, Inc. (SING) provides mobile technology and marketing solutions that enable companies, nonprofits and religious organizations to conduct business transactions, accept donations, and engage in targeted communication via mobile devices. Through diversification of its own model, the company is also leveraging its core technology to expand into the mobile auctions and daily fantasy sports markets.

SING currently has two fundraising solutions. Text2Bid is an interactive way to increase auction revenues. The technology makes it easy for people to bid in auctions from any text or web-enabled phone. Donate by Text allows nonprofits to securely collect one-time or recurring donations via text. This capability creates a personal experience for the donors, and enables ongoing communication between the donor and nonprofit or event sponsor.

SING's payment solutions include point-of-sale (POS) terminals, loyalty programs, payment processing, phone services and financing. Pay by Text™ enables a business to accept payment transactions and, in essence, turns the user's mobile phone into a point-of-sale device. Operating on the same platform as mobile marketing, Pay by Text is designed to increase revenues, raise the average per-transaction amount, and create a fast, easy and hassle-free method of payment.

As part of its diversification and expansion strategy, SING recently acquired an interest in DraftFury (www.draftfury.com), a company that offers skill-based NBA, NFL and MLB daily fantasy sports (DFS) contests. DraftFury is known for its innovative offerings and originality, and is the first cash-flow-positive DFS enterprise. This transaction places SING in a multi-billion dollar industry expected to generate entry fees of $14.4 billion in 2020. Under the guidance of a leadership team well-versed in technology, engineering, marketing and raising capital, SING anticipates a strong foothold in its chosen markets. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

SinglePoint, Inc. Gains Focus in NetworkNewsWire Publication Discussing How Innovators in the Diverse Marijuana Industry are Building Corporate Value

SinglePoint Signs Reseller Agreement for High Risk Merchant Processing

SinglePoint Targets Cannabis Dispensaries with SingleSeed -- CFN Media

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.3702, up 2.83%, on 38,199 volume with 15 trades. The stock’s average daily volume over the past 60 days is 188,013 and its 52-week low/high is $0.05/$2.09.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub (ORHB) Enhances Leading Data Analytics Platform with Integration of Sterilization Process Module

ORHub (ORHB) Appoints New Chief Operating Officer to Facilitate Growth Strategies

Significant Milestone Helps ORHub (ORHB) Deliver Cost-cutting Insight to Health Care Providers

InMed Pharmaceuticals, Inc. (IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.4124, up 1.83%, on 203,600 volume with 113 trades. The stock’s average daily volume over the past 60 days is 1,096,855, and its 52-week low/high is $0.05/$0.72.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Pharmaceuticals Files Provisional Patent Application for Ophthalmic Drug Delivery

InMed Pharmaceuticals' Unique Approach Featured in Forbes -- CFN Media

InMed's Exceptional Management Team Executes Ambitious Plan -- CFN Media

National Waste Management Holdings, Inc. (NWMH)

The QualityStocks Daily Newsletter would like to spotlight National Waste Management Holdings, Inc. (NWMH). Today, National Waste Management Holdings, Inc. closed trading at $0.099, even for the day. The stock’s average daily volume over the past 60 days is 20,726, and its 52-week low/high is $0.06/$0.41.

National Waste Management Holdings, Inc. (NWMH) is a solid waste management company offering comprehensive solutions for full waste diversion along Florida's west coast and in upstate New York. With an established base of long-term partnerships with municipal, institutional, commercial and industrial customers, along with a successful acquisition strategy, National Waste has set its course to become a leading waste diversion company.

National Waste's 54-acre landfill facility located in Hernando, Florida, handles annual average disposals of roughly 240,000 cubic yards of construction debris annually. The site also offers an array of ancillary services such as roll-off dumpster services, mulching services and recycling. While the landfill facility is already permitted for future expansion, National Waste's growth strategy also calls for the opening of new satellite offices in counties and states that neighbor its existing operations.

In addition to increasing its geographic foothold, National Waste employs a strategic acquisition model to increase its overall market share. In 2015, the company acquired Gateway Rolloff Services LP and Waste Recovery Enterprises LLC, which are expected to generate a combined $3.8 million in annual revenue for National Waste moving forward. In the second quarter of 2016, National Waste added Sivart Services to its roster, creating an immediate source of additional revenue and expanding its foothold in the northeast area of New York.

Management has confirmed its interest in additional acquisition targets while demonstrating its ability to effectively integrate and organically grow the company's existing acquisition companies and maintain efficient operations. Disclaimer

National Waste Management Holdings, Inc. Company Blog

National Waste Management Holdings, Inc. News:

National Waste Management Holdings Inc. Reports Full-Year 2016 Results, Triple-Digit Revenue Growth

National Waste Management Holdings, Inc. Expands Territory with Acquisition of Burts Refuse, LLC

National Waste Management Holdings, Inc. (NWMH) Expands Market Reach in New York with Acquisition of Northeast Data Destruction and Recycling


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(UVND) +84.05%


(ELECW) +53.33%


(OBLR) +50.00%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251